Business
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence
About this update from Lantern Pharma Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management and employees will be presenting at three upcoming events:\n\n\nRare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET. Panna Sharma, CEO & President, will present.\nSession Title: Using AI to Accelerate the Drug Discovery and Development Process for Rare Cancers\nRegistration Link: https://informaconnect.com/rare-disease-summit/pricing/\n\n\n\n\nHow Artificial Intelligence Is Changing Drug Discovery Webinar on Thursday, March 23 at 1:00 p.m. ET. Panna Sharma, CEO & President, will be a panelist. The free webinar is co-hosted by the Science History Institute and the American Chemical Society.\nWebinar Link: https://www.eventbrite.com/e/how-artificial-intelligence-is-changing-drug-discovery\n\n\n\n\nGenomics in Precision Oncology Xchange East Coast in Boston, MA on Wednesday, April 5 at 9:05 a.m. ET. Peter Carr, Principal Software Architect, will moderate a session for genomics informed clinical decisions.\nSession Title: Clinical trial design & its use in silico modeling for combination therapies\nRegistration Link: https://www.hub-xchange.com/genomics-in-precision-oncology-east-coast-2023/\n\n\nAbout Lantern Pharma:\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.\n\nPlease find more information at:\nWebsite: www.lanternpharma.com\nLinkedIn: https://www.linkedin.com/company/lanternpharma/\nTwitter: @lanternpharma\nLantern Pharma Newsletter – The Spark: Sign-up here\n\nForward-looking Statements:\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of ...